Verastem

VSTM Lead: Approved 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-04

Catalyst timeline

VS-7375 enrollment doneBy end of 2026VS-7375 enrollment done, By end of 2026, notable
VS-7375 interimOct 2026VS-7375 interim, Oct 2026, major
VS-7375 Ph3 start1H 2027VS-7375 Ph3 start, 1H 2027, notable
Avutometinib + defactinib RAMP Ph3mid-2027Avutometinib + defactinib RAMP Ph3, mid-2027, major
Oberland optional tranche corporate updateMay 15, 2027Oberland optional tranche corporate update, May 15, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

AVMAPKI

FAKZYNJA · AVMAPKI FAKZYNJA CO-PACK · avutometinib · defactinib

Small Molecule Target: RAF, MEK, FAK

Low-Grade Serous Ovarian Cancer Approved oral Chugai Pharmaceutical NCT01778803

AVMAPKI

FAKZYNJA · avutometinib · defactinib

Small Molecule Target: RAF, MEK, FAK

Pancreatic Ductal Adenocarcinoma Phase 2 Phase 1b/2a trial oral NCT02546531

VS-7375

Small Molecule Target: KRAS G12D

Pancreatic Ductal Adenocarcinoma Phase 2 Phase 1/2 trial oral GenFleet Therapeutics NCT07020221
Non-Small Cell Lung Cancer Phase 2 Phase 1/2 trial oral GenFleet Therapeutics NCT07659782
Colorectal Cancer Phase 2 Phase 1/2 trial oral GenFleet Therapeutics NCT07020221

Discontinued (1)

avutometinib — Non-Small Cell Lung Cancer · discontinued RAMP 203 to focus resources on VS-7375 development; evolving treatment landscape for KRAS G12C inhibitors

Biotech Distilled coverage (2)

2026-08-07 UPDATE: Verastem Oncology (VSTM) - The Dilution Gap Gets Papered Over 🔒 Paid
2026-07-20 Verastem Oncology (VSTM) — Scientific Deep Dive for AVMAPKI FAKZYNJA CO-PACK (Avutometinib + Defactinib) and VS-7375 (Oral KRAS G12D) 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.